Coalition to Cure Calpain 3 (C3) is pleased to announce that Dr. Stefanie Müthel was awarded a Travel Grant for the presentation of her research at the Biology of Calpains in Health and Disease Conference in Pacific Grove, California, from July 14-19, 2019.
Dr. Müthel is a postdoctoral researcher in the laboratory of Dr. Simone Spuler at the Experimental and Clinical Research Center, a join cooperation of the Charité Medical Faculty and the Max-Delbrück-Center for Molecular Medicine in Berlin, Germany. She was selected for both poster and oral presentations at the conference, which covered not only Calpain 3 and Limb-Girdle Muscular Dystrophy type 2A (LGMD2A), but also the function of other calpains in neurodegenerative, gastrointestinal, and eye diseases. The meeting was co-organized by C3 Scientific Advisory Board Chair Dr. Melissa Spencer, and C3 Scientific Director Dr. Jennifer Levy was in attendance.
Dr. Müthel’s research aims to develop a method to repair the mutation CAPN3c.550delA by using the gene editing technology CRISPR. Approximately 30% of LGMD2A patients carry this mutation, making it the most common mutation associated with the disease. She is performing experiments in cells derived from muscle biopsies taken from LGMD2A patients.
The goal of the C3 Travel Grant program is to foster early career investigators who are currently conducting research in the area of LGMD2A or Calpain 3. The grants support travel expenses to attend relevant conferences to present the investigator’s ongoing work. Grant applications are being accepted on a rolling basis through May 2020.